Transforming growth factor beta inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Transforming growth factor beta inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs based on Transforming growth factor beta inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Transforming growth factor beta inhibitors: Overview
Transforming growth factor-? (TGF-?) regulates cell growth and differentiation, apoptosis, cell motility, extracellular matrix production, angiogenesis, and cellular immunity. It has a paradoxical role in cancer. In the early stages it inhibits cellular transformation and prevents cancer progression. In later stages TGF-? plays a key role in promoting tumor progression through mainly 3 mechanisms: facilitating epithelial to mesenchymal transition, stimulating angiogenesis and inducing immunosuppression. As a result of its opposing tumor promoting and tumor suppressive abilities, TGF-? and its pathway has represented potential opportunities for drug development and several therapies targeting the TGF-? pathway have been identified. This review focuses on identifying the mechanisms through which TGF-? is involved in tumorigenesis and current therapeutics that are under development.
Transforming growth factor beta inhibitors Emerging Drugs Chapters
This segment of the Transforming growth factor beta inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Transforming growth factor beta inhibitors Emerging Drugs
Further product details are provided in the report……..
Transforming growth factor beta inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Transforming growth factor beta inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Transforming growth factor beta inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Transforming growth factor beta inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Transforming growth factor beta inhibitors drugs.
Report Highlights
DelveInsight’s, “Transforming growth factor beta inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs based on Transforming growth factor beta inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Transforming growth factor beta inhibitors: Overview
Transforming growth factor-? (TGF-?) regulates cell growth and differentiation, apoptosis, cell motility, extracellular matrix production, angiogenesis, and cellular immunity. It has a paradoxical role in cancer. In the early stages it inhibits cellular transformation and prevents cancer progression. In later stages TGF-? plays a key role in promoting tumor progression through mainly 3 mechanisms: facilitating epithelial to mesenchymal transition, stimulating angiogenesis and inducing immunosuppression. As a result of its opposing tumor promoting and tumor suppressive abilities, TGF-? and its pathway has represented potential opportunities for drug development and several therapies targeting the TGF-? pathway have been identified. This review focuses on identifying the mechanisms through which TGF-? is involved in tumorigenesis and current therapeutics that are under development.
Transforming growth factor beta inhibitors Emerging Drugs Chapters
This segment of the Transforming growth factor beta inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Transforming growth factor beta inhibitors Emerging Drugs
- Trabedersen: Oncotelic
- KER-050: Keros Therapeutics
- STP705: Sirnaomics
Further product details are provided in the report……..
Transforming growth factor beta inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Transforming growth factor beta inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Transforming growth factor beta inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Transforming growth factor beta inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Transforming growth factor beta inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Transforming growth factor beta inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Transforming growth factor beta inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Sirnaomics announced that the Office of Orphan Product Development division of the FDA has granted orphan drug designation to its leading therapeutic candidate, STP705, for the treatment of Hepatocellular Carcinoma (HCC).
- In August 2017, Sirnaomics stated that the Office of Orphan Product Development division of the USA FDA has granted Orphan Drug Designation to its leading therapeutic candidate, STP705, for the treatment of Primary Sclerosing Cholangitis (PSC).
- Trabedersen (OT-101) has strong Patent protection until 2037 and has received Orphan designation granted for three tumor indications in US & EU.
- Transforming growth factor beta inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
- What are the current treatment options available based on the Transforming growth factor beta inhibitors?
- How many companies are developing therapies by working on Transforming growth factor beta inhibitors?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for Transforming growth factor beta inhibitors to treat disease condition?
- How many emerging therapies are in early-stage, mid-stage, and late stage of development for Transforming growth factor beta inhibitors?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Transforming growth factor beta inhibitors therapies?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies developed based on this mechanism of action?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Transforming growth factor beta inhibitors and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Transforming growth factor beta inhibitors?
- How many patents are granted and pending for the emerging therapies of Transforming growth factor beta inhibitors?
- Oncotelic
- Jiangsu Hengrui Medicine Co
- Bristol-Myers Squibb/Rigel.
- Biogen Idec
- Genentech
- Tilos Therapeutics
- Eli Lilly and Company
- Trabedersen
- SHR 1701
- Research programme: transforming growth factor beta receptor kinase inhibitors
- Research programme: transforming growth factor beta-1 receptor antagonists
- Anti-TGF-beta monoclonal antibody 2G7
- TL 02
- TL 03
- LY 3200882
Introduction
Executive Summary
Transforming growth factor beta inhibitors: Overview
Structure
Mechanism of Action
Classification
Application
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Transforming growth factor beta inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Transforming growth factor beta inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Transforming growth factor beta inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Trabedersen: Oncotelic
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
KER-050: Keros Therapeutics
Product Description
Research and Development
Product Development Activities
STP705: Sirnaomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Transforming growth factor beta inhibitors Key Companies
Transforming growth factor beta inhibitors Key Products
Transforming growth factor beta inhibitors- Unmet Needs
Transforming growth factor beta inhibitors- Market Drivers and Barriers
Transforming growth factor beta inhibitors- Future Perspectives and Conclusion
Transforming growth factor beta inhibitors Analyst Views
Transforming growth factor beta inhibitors Key Companies
Appendix
Executive Summary
Transforming growth factor beta inhibitors: Overview
Structure
Mechanism of Action
Classification
Application
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Transforming growth factor beta inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Transforming growth factor beta inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Transforming growth factor beta inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Trabedersen: Oncotelic
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
KER-050: Keros Therapeutics
Product Description
Research and Development
Product Development Activities
STP705: Sirnaomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Transforming growth factor beta inhibitors Key Companies
Transforming growth factor beta inhibitors Key Products
Transforming growth factor beta inhibitors- Unmet Needs
Transforming growth factor beta inhibitors- Market Drivers and Barriers
Transforming growth factor beta inhibitors- Future Perspectives and Conclusion
Transforming growth factor beta inhibitors Analyst Views
Transforming growth factor beta inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Transforming growth factor beta inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Transforming growth factor beta inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Transforming growth factor beta inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Transforming growth factor beta inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products